Daraxonrasib Shows Promising Results in Metastatic Pancreatic Cancer Treatment
Daraxonrasib significantly extends survival in metastatic pancreatic cancer
Image: Medical News
At the ASCO Annual Meeting, results from the RASolute 302 trial revealed that daraxonrasib, an investigational oral RAS inhibitor, significantly improves survival rates in patients with previously treated metastatic pancreatic cancer compared to standard chemotherapy. This breakthrough could redefine treatment protocols for this challenging disease.
- 01Daraxonrasib demonstrated a median overall survival of 13.2 months compared to 6.7 months for chemotherapy.
- 02The trial involved 500 patients across North America, Europe, and Asia, all previously treated with one line of chemotherapy.
- 03Patients receiving daraxonrasib had a 31.6% objective response rate, significantly higher than the 11.2% observed with chemotherapy.
- 04The most common side effects of daraxonrasib included rash, mouth inflammation, nausea, and diarrhea, with no unexpected safety findings.
- 05The FDA has approved an expanded access program for daraxonrasib, marking a potential shift in treatment standards for metastatic pancreatic cancer.
Advertisement
In-Article Ad
At the upcoming ASCO Annual Meeting, Brian Wolpin, MD, MPH, from Dana-Farber Cancer Institute, will present findings from the RASolute 302 trial, which indicate that daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, significantly extends survival in patients with previously treated metastatic pancreatic cancer. The trial results show that patients treated with daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. Additionally, the objective response rate for daraxonrasib was 31.6%, far exceeding the 11.2% rate for chemotherapy. The trial enrolled 500 patients globally, all of whom had undergone prior chemotherapy. Daraxonrasib was well tolerated, with manageable side effects, and no unexpected safety issues were reported. This marks a pivotal moment in pancreatic cancer treatment, potentially establishing daraxonrasib as the new standard of care for second-line therapy. The FDA has also permitted an expanded access program for this drug, emphasizing its promising role in improving patient outcomes.
Advertisement
In-Article Ad
The introduction of daraxonrasib could significantly improve treatment outcomes for patients with metastatic pancreatic cancer, a condition known for its poor prognosis.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of daraxonrasib in treating pancreatic cancer?
Connecting to poll...
More about Dana-Farber Cancer Institute
Read the original article
Visit the source for the complete story.